Page last updated: 2024-09-05

varenicline and Cardiovascular Diseases

varenicline has been researched along with Cardiovascular Diseases in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (7.81)	29.6817
2010's	55 (85.94)	24.3611
2020's	4 (6.25)	2.80

Authors

Authors	Studies
Choi, SKY; Chow, CK; Filion, KB; Havard, A; Pearson, SA; Tran, DT	1
Chow, CK; Falster, MO; Filion, KB; Havard, A; Hsu, B; Jorm, L; Pearson, SA; Robijn, AL; Woodward, M	1
Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Taylor, S	1
Inada, K; Kanaoka, Y; Kataoka, Y; Koga, M; Omine, S; Yamauchi, A	1
Kotz, D; Sheikh, A; Simpson, CR; van Schayck, OCP; Viechtbauer, W; West, R	1
Galanti, MR; Hansson, J; Janszky, I; Möller, J; Monárrez-Espino, J; Söderberg-Löfdal, K	1
Campitelli, MA; Gershon, AS; Hawken, S; Kurdyak, P; Selby, P; Sproule, BA; Victor, C	1
Anthenelli, RM; Benowitz, NL; Hays, JT; Lawrence, D; McRae, T; Pipe, A; St Aubin, L; Tonstad, S; West, R	1
Fujimi, K; Imaizumi, S; Kamizono, Y; Kuwano, T; Miura, SI; Noda, K; Saku, K; Shiga, Y; Suematsu, Y; Tsukahara, H	1
Baker, MA; Brown, JS; Kornegay, C; Platt, R; Toh, S	1
Bawagan, J	1
Clair, C; Rigotti, NA	1
Boomershine, V; Haber, SL; Raney, E	1
Allan, GM; McCormack, J; Vandermeer, B	1
Eapen, S; Mills, EJ; Prochaska, JJ; Thorlund, K; Wu, P	1
Brusaferro, S; De Bacquer, D; de Velasco, J; Hoes, A; Jennings, C; Jones, J; Kotseva, K; Mead, A; Tonstad, S; Wood, D	1
Kmeťová, A; Králíková, E; Zvolská, K	1
By, K; Graham, DJ; Kelman, JA; Kornegay, C; Levenson, M; MaCurdy, TE; McKean, S; Mosholder, A; Racoosin, JA; Worrall, C; Young, J	1
Abe, S; Imaizumi, S; Kawachi, E; Matsuo, Y; Miura, S; Noda, K; Saku, K; Shimizu, T; Suematsu, Y; Takata, K; Tsukahara, H; Uehara, Y; Yahiro, E; Zhang, B	1
Kanaoka, Y; Kataoka, Y; Koga, M; Kubo, N; Ohishi, K; Ohkido, Y; Sugiyama, K; Yamauchi, A	1
Azrin, ST; Baller, J; Daumit, GL; Juliano-Bult, D; McGinty, EE	1
Kotz, D; Sheikh, A; Simpson, C; van Schayck, OC; Viechtbauer, W; West, R	3
Leone, FT; Schnoll, R	1
Ermiş, N; Karatas, M; Kayhan-Tetik, B; Parlakpinar, H; Polat, A; Sagır, M; Selçuk, EB; Sungu, M; Taslıdere, E; Vardı, N; Yalçınsoy, M	1
Burden, AM; Nielen, JT	1
Odeyale, F; Udo, I	1
Davies, NM; Martin, RM; Munafò, MR; Taylor, AE; Taylor, G; Thomas, KH	1
Abe, TO; Gaya, PV; Pereira, AC; Pinheiro, GG; Santos, PC; Scholz, J; Silva, AP	1
Eisenberg, MJ; Filion, KB; Sterling, LH; Touma, L; Windle, SB	1
Anand, A; Fidler, L; Stanbrook, M	1
Azoulay, L; Eberg, M; Filion, KB	1
Achtyes, ED; Cather, C; Evins, AE; Hoeppner, SS; Pachas, GN; Pratt, S; Thorndike, AN	1
Cedillo, S; Fernández de Bobadilla, J; Jiménez-Ruiz, CA; Rejas-Gutiérrez, J; Sicras-Mainar, A	1
Eberg, M; Eisenberg, MJ; Filion, KB; Gore, GC; Grad, R; Joseph, L; Larivière, J; Reynier, PM; Suissa, K	1
Mafé, C; Tornero, C	1
Burke, MV; Ebbert, JO; Hays, J; Wyatt, KD; Zirakzadeh, A	1
Ockene, I; Salmoirago-Blotcher, E	1
Arteaga, C; Benowitz, NL; Garza, D; Pipe, AL; Rigotti, NA; Tonstad, S	1
Ioannides-Demos, LL; McNeil, JJ; Piccenna, L	1
Pelle, AJ; Smolderen, KG	1
Furberg, CD; Loke, YK; Singh, S; Spangler, JG	1
Hays, JT	1
Annemans, L; Diaz Cerezo, S; Hettle, R; Ines, M; Lopez de Sa, E; Marbaix, S; Prignot, J; Santoni, L; Wilson, K	1
Squire, EN	1
Caswell, MD; Woods, DJ	1
Takagi, H; Umemoto, T	1
Blankfield, RP	1
Alper, BS	1
Samuels, L	1
Ashton, J; Harrison-Woolrych, M; Maggo, S; Savage, R; Tan, M	1
Cuesta, G; Lovato, P; Lutz, MA	1
Goldstein, AO; Kistler, CE	1
Hilton, JF; Prochaska, JJ	1
Hviid, A; Pasternak, B; Svanström, H	1
Harrison-Woolrych, M	1
Arnsten, JH; Bernstein, SL; Nahvi, S; Richter, KP; Wu, B	1
Bullen, C; Fagerström, K; McRobbie, H; Whittaker, R	1
Pipe, AL; Quinlan, B; Reid, RD; Riley, DL	1
Anthenelli, RM	1

Reviews

13 review(s) available for varenicline and Cardiovascular Diseases

Article	Year
Managing tobacco use: the neglected cardiovascular disease risk factor. European heart journal, 2013, Volume: 34, Issue:42 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Counseling; Female; Health Promotion; Humans; Male; Nicotinic Agonists; Physician's Role; Quinoxalines; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Smoke Pollution; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2013
Safety of varenicline in patients with cardiovascular disease. Journal of pharmacy practice, 2014, Volume: 27, Issue:1 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Risk; Smoking; Smoking Cessation; Smoking Prevention; Varenicline	2014
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation, 2014, Jan-07, Volume: 129, Issue:1 Topics: Adult; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; Male; Nicotine; Nicotinic Agonists; Quinoxalines; Risk Factors; Smoking; Smoking Cessation; Varenicline	2014
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review. Schizophrenia bulletin, 2016, Volume: 42, Issue:1 Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine Uptake Inhibitors; Health Behavior; HIV Infections; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Motor Activity; Nicotinic Agonists; Obesity; Overweight; Risk Reduction Behavior; Schizophrenia; Smoking; Smoking Cessation; Varenicline	2016
Cardiac adverse effects of nicotine replacement therapy. Prescrire international, 2015, Volume: 24, Issue:166 Topics: Bupropion; Cardiovascular Diseases; Humans; Tobacco Use Cessation Devices; Varenicline	2015
Varenicline and Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2016, Feb-22, Volume: 5, Issue:2 Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Odds Ratio; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Smoking Prevention; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline; Young Adult	2016
Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. Circulation. Cardiovascular quality and outcomes, 2017, Volume: 10, Issue:1 Topics: Bupropion; Cardiovascular Diseases; Counseling; Humans; Network Meta-Analysis; Nicotinic Agonists; Odds Ratio; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Risk Reduction Behavior; Smoking; Smoking Cessation; Smoking Prevention; Time Factors; Varenicline	2017
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. International journal of chronic obstructive pulmonary disease, 2009, Volume: 4 Topics: Benzazepines; Cardiovascular Diseases; Drug Labeling; Humans; Mental Disorders; Nicotinic Agonists; Pulmonary Disease, Chronic Obstructive; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2009
Smoking cessation-recent advances. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Australia; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Humans; Immunotherapy, Active; Nicotine; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Transdermal Patch; Treatment Outcome; United Kingdom; United States; Varenicline	2010
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Randomized Controlled Trials as Topic; Risk; Varenicline	2011
Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ (Clinical research ed.), 2012, May-04, Volume: 344 Topics: Adult; Benzazepines; Cardiovascular Diseases; Female; Humans; Male; Nicotinic Agonists; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Tobacco Use Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline	2012
A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease. Preventive cardiology, 2007,Spring, Volume: 10, Issue:2 Suppl 1 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Directive Counseling; Hospitalization; Humans; Neurotransmitter Uptake Inhibitors; Nicotinic Agonists; Nortriptyline; Quinoxalines; Referral and Consultation; Risk Reduction Behavior; Smoking; Smoking Cessation; Varenicline	2007
Smoking cessation: lessons learned from clinical trial evidence. Current opinion in cardiology, 2007, Volume: 22, Issue:4 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dopamine Uptake Inhibitors; Humans; Nicotinic Agonists; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking; Smoking Cessation; Smoking Prevention; Varenicline	2007

Trials

7 trial(s) available for varenicline and Cardiovascular Diseases

Article	Year
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA internal medicine, 2018, 05-01, Volume: 178, Issue:5 Topics: Bupropion; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Risk Factors; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Varenicline	2018
Impact of cigarette smoking cessation on plasma α-klotho levels. Medicine, 2018, Volume: 97, Issue:35 Topics: Adult; Blood Pressure; Cardiovascular Diseases; Cigarette Smoking; Female; Fibroblast Growth Factors; Glucuronidase; Heart Rate; Humans; Klotho Proteins; Male; Middle Aged; Nicotinic Agonists; Risk Factors; Smoking Cessation; Tobacco Use Cessation Devices; Treatment Outcome; Varenicline	2018
Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial. European heart journal, 2014, Jun-01, Volume: 35, Issue:21 Topics: Benzazepines; Cardiovascular Diseases; Diet; Exercise Therapy; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Quinoxalines; Risk Reduction Behavior; Smoking; Smoking Cessation; Smoking Prevention; Treatment Outcome; Varenicline	2014
Impact of cigarette smoking cessation on high-density lipoprotein functionality. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Cutaneous; Adult; Apolipoprotein A-I; Benzazepines; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholinergic Agonists; Female; Humans; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, HDL; Macrophages; Male; Malondialdehyde; Middle Aged; Nicotine; Oxidation-Reduction; Quinoxalines; Receptors, Nicotinic; Risk Factors; Smoking; Smoking Cessation; Varenicline	2014
Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. The Journal of clinical psychiatry, 2016, Volume: 77, Issue:3 Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypertension; Male; Mental Disorders; Middle Aged; Obesity; Remission Induction; Smoking Cessation; Varenicline; Weight Gain	2016
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation, 2010, Jan-19, Volume: 121, Issue:2 Topics: Aged; Benzazepines; Cardiovascular Diseases; Directive Counseling; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Quinoxalines; Smoking Cessation; Survival Rate; Treatment Outcome; Varenicline	2010
An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. European journal of preventive cardiology, 2012, Volume: 19, Issue:5 Topics: Belgium; Benzazepines; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Humans; Italy; Male; Middle Aged; Nicotinic Agonists; Portugal; Prevalence; Quality of Life; Quinoxalines; Smoking; Smoking Cessation; Spain; Treatment Outcome; Varenicline	2012

Other Studies

44 other study(ies) available for varenicline and Cardiovascular Diseases

Article	Year
Comparison of Cardiovascular Safety for Smoking Cessation Pharmacotherapies in a Population-Based Cohort in Australia. JAMA network open, 2021, 11-01, Volume: 4, Issue:11 Topics: Adult; Bupropion; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Middle Aged; New South Wales; Retrospective Studies; Smoking; Smoking Cessation Agents; Varenicline	2021
Comparative effect of varenicline and nicotine patches on preventing repeat cardiovascular events. Heart (British Cardiac Society), 2023, 06-14, Volume: 109, Issue:13 Topics: Aftercare; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Nicotine; Nicotinic Agonists; Patient Discharge; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline	2023
Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. Addiction (Abingdon, England), 2020, Volume: 115, Issue:8 Topics: Adolescent; Adult; Aged; Bupropion; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Retrospective Studies; Smoking Cessation; Smoking Cessation Agents; Tobacco Use Cessation Devices; Tobacco Use Disorder; United States; Varenicline; Young Adult	2020
Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages. Journal of pharmacological sciences, 2020, Volume: 143, Issue:2 Topics: Animals; Apolipoproteins E; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cardiovascular Diseases; CD36 Antigens; Down-Regulation; Hesperidin; Lipoproteins, LDL; Macrophages; Mice; Mice, Knockout; Plaque, Atherosclerotic; RAW 264.7 Cells; Scavenger Receptors, Class E; Varenicline	2020
Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax, 2017, Volume: 72, Issue:10 Topics: Adult; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; England; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Propensity Score; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Risk Factors; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline	2017
Treatment With Bupropion and Varenicline for Smoking Cessation and the Risk of Acute Cardiovascular Events and Injuries: a Swedish Case-Crossover Study. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2018, 04-02, Volume: 20, Issue:5 Topics: Accidental Falls; Accidents, Traffic; Adult; Bupropion; Cardiovascular Diseases; Cross-Over Studies; Humans; Smoking Cessation; Smoking Cessation Agents; Substance Withdrawal Syndrome; Suicide, Attempted; Sweden; Tobacco Use Disorder; Varenicline; Wounds and Injuries	2018
Cardiovascular and Neuropsychiatric Events after Varenicline Use for Smoking Cessation. American journal of respiratory and critical care medicine, 2018, 04-01, Volume: 197, Issue:7 Topics: Aged; Cardiovascular Diseases; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Ontario; Smoking Cessation; Varenicline	2018
Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. JAMA internal medicine, 2013, May-13, Volume: 173, Issue:9 Topics: Adult; Aged; Benzazepines; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Drug Prescriptions; Female; Humans; Male; Middle Aged; Nicotinic Agonists; Product Surveillance, Postmarketing; Quinoxalines; Risk Assessment; Risk Factors; Sentinel Surveillance; Smoking Cessation; Tobacco Use Disorder; United States; United States Food and Drug Administration; Varenicline	2013
Systematic review wins CMAJ Bruce Squires Award. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, May-14, Volume: 185, Issue:8 Topics: Awards and Prizes; Benzazepines; Canada; Cardiovascular Diseases; Humans; Nicotinic Agonists; Publications; Quinoxalines; Smoking Cessation; Varenicline	2013
How confidence intervals become confusion intervals. BMC medical research methodology, 2013, Oct-31, Volume: 13 Topics: Anticoagulants; Benzazepines; Cardiovascular Diseases; Confidence Intervals; Data Interpretation, Statistical; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quinoxalines; Randomized Controlled Trials as Topic; Risk; Treatment Outcome; Uncertainty; Varenicline	2013
[Vareniklin: a safe treatment of tobacco dependency for cardiovascular patients]. Casopis lekaru ceskych, 2014, Volume: 153, Issue:3 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Risk Factors; Risk Reduction Behavior; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline	2014
Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:11 Topics: Aged; Aged, 80 and over; Benzazepines; Bupropion; Cardiovascular Diseases; Cohort Studies; Comorbidity; Female; Humans; Incidence; Male; Medicare; Nicotinic Agonists; Quinoxalines; Smoking Cessation; United States; Varenicline	2014
Varenicline aggravates plaque formation through α7 nicotinic acetylcholine receptors in ApoE KO mice. Biochemical and biophysical research communications, 2014, Dec-12, Volume: 455, Issue:3-4 Topics: Aconitine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Apolipoproteins E; Benzazepines; Body Weight; Cardiovascular Diseases; Cholesterol; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotinic Agonists; Plaque, Atherosclerotic; Quinoxalines; Varenicline	2014
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:10 Topics: Adult; Bupropion; Cardiovascular Diseases; Depression; Dopamine Uptake Inhibitors; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotinic Agonists; Retrospective Studies; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline	2015
Reframing the varenicline question: have anecdotes and emotional filters clouded our decision making? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:10 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Evaluation of the cardiovascular effects of varenicline in rats. Drug design, development and therapy, 2015, Volume: 9 Topics: Animals; Antioxidants; Aorta; Apoptosis; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Caspase 9; Heart; Heart Rate; Lipid Peroxidation; Myocardium; Nicotinic Agonists; Oxidative Stress; Rats, Wistar; Risk Assessment; Time Factors; Tobacco Use Cessation Devices; Varenicline; Weight Loss	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? - Authors' reply. The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:12 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2015
Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting. BMC cardiovascular disorders, 2016, Jan-05, Volume: 16 Topics: Adult; Aged; Blood Pressure; Brazil; Bupropion; Cardiovascular Diseases; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Diastole; Dopamine Uptake Inhibitors; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nicotine; Nicotinic Agonists; Risk Factors; Smoking; Smoking Cessation; Systole; Tobacco Use Cessation Devices; Varenicline	2016
Cardiovascular and neuropsychiatric risks of varenicline - Authors' reply. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:3 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2016
Cardiovascular and neuropsychiatric risks of varenicline. The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:3 Topics: Cardiovascular Diseases; Female; Humans; Male; Mental Disorders; Nicotinic Agonists; Tobacco Use Cessation Devices; Varenicline	2016
Cardiovascular Safety Warnings and the Prescribing of Varenicline: An Interrupted Time-series Analysis. Epidemiology (Cambridge, Mass.), 2016, Volume: 27, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Drug Approval; Drug Labeling; Drug Utilization; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Tobacco Use Cessation Devices; Varenicline; Young Adult	2016
Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective. European addiction research, 2017, Volume: 23, Issue:1 Topics: Adult; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Pulmonary Disease, Chronic Obstructive; Smoking Cessation; Spain; Varenicline	2017
Varenicline and antiretroviral therapy in patients with HIV. Journal of acquired immune deficiency syndromes (1999), 2009, Volume: 52, Issue:5 Topics: Anti-Retroviral Agents; Benzazepines; Cardiovascular Diseases; Female; HIV Infections; Humans; Male; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline	2009
Varenicline for smoking cessation in patients with coronary heart disease. Circulation, 2010, Jan-19, Volume: 121, Issue:2 Topics: Benzazepines; Cardiovascular Diseases; Coronary Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Quinoxalines; Smoking Cessation; Treatment Outcome; Varenicline	2010
Letter by Smolderen and Pelle regarding article, "Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial". Circulation, 2010, Aug-31, Volume: 122, Issue:9 Topics: Benzazepines; Cardiovascular Diseases; Depression; Humans; Nicotinic Agonists; Patient Selection; Quinoxalines; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Smoking Cessation; Varenicline	2010
Varenicline for smoking cessation: is it a heartbreaker? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
In brief: Cardiovascular safety of varenicline (Chantix). The Medical letter on drugs and therapeutics, 2011, Aug-22, Volume: 53, Issue:1371 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline	2011
Varenicline: quantifying the risk. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
Varenicline: quantifying the risk. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
Varenicline: quantifying the risk. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
Varenicline: quantifying the risk. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
Varenicline: quantifying the risk. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
Varenicline: cardiovascular safety. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Sep-06, Volume: 183, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Humans; Nicotinic Agonists; Quinoxalines; Varenicline	2011
More evidence that varenicline harms the heart. The Harvard mental health letter, 2011, Volume: 28, Issue:4 Topics: Benzazepines; Cardiovascular Diseases; Humans; Meta-Analysis as Topic; Nicotinic Agonists; Quinoxalines; Smoking Cessation; Varenicline	2011
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug safety, 2012, Jan-01, Volume: 35, Issue:1 Topics: Adult; Aged; Benzazepines; Cardiovascular Diseases; Cohort Studies; Female; Humans; Male; Middle Aged; New Zealand; Nicotinic Agonists; Product Surveillance, Postmarketing; Prospective Studies; Quinoxalines; Smoking Cessation; Surveys and Questionnaires; Varenicline	2012
Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model. Hospital practice (1995), 2012, Volume: 40, Issue:1 Topics: Benzazepines; Bupropion; Cardiovascular Diseases; Central America; Cost-Benefit Analysis; Dominican Republic; Dopamine Uptake Inhibitors; Health Expenditures; Humans; Lung Neoplasms; Nicotinic Agonists; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinoxalines; Smoking; Smoking Cessation; Tobacco Use Cessation Devices; Varenicline	2012
The risk of adverse cardiovascular events from varenicline balanced against the benefits in mortality from smoking cessation. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2012, Volume: 14, Issue:12 Topics: Benzazepines; Cardiovascular Diseases; Female; Humans; Middle Aged; Nicotinic Agonists; Quinoxalines; Risk Assessment; Smoking; Smoking Cessation; Varenicline	2012
Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ (Clinical research ed.), 2012, Nov-08, Volume: 345 Topics: Acute Coronary Syndrome; Adult; Age Distribution; Aged; Benzazepines; Bupropion; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confidence Intervals; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Quinoxalines; Retrospective Studies; Risk Assessment; Sex Distribution; Smoking Cessation; Stroke; Survival Analysis; Varenicline	2012
Varenicline for smoking cessation. BMJ (Clinical research ed.), 2012, Nov-08, Volume: 345 Topics: Benzazepines; Cardiovascular Diseases; Drug Approval; Drug Monitoring; Female; Humans; Male; Needs Assessment; New Zealand; Nicotinic Agonists; Quinoxalines; Risk Assessment; Smoking Cessation; Suicidal Ideation; United States; United States Food and Drug Administration; Varenicline	2012
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness. Drug and alcohol dependence, 2013, Sep-01, Volume: 132, Issue:1-2 Topics: Benzazepines; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Female; Humans; Longitudinal Studies; Male; Mental Disorders; Methadone; Middle Aged; Narcotics; Nicotinic Agonists; Opioid-Related Disorders; Prevalence; Primary Health Care; Quinoxalines; Smoking; Smoking Cessation; Socioeconomic Factors; Treatment Outcome; Varenicline	2013
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence. Nature clinical practice. Cardiovascular medicine, 2007, Volume: 4, Issue:9 Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline	2007